Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.63 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | PRNP | P04156 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.56 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484085 | 0.87 | GPR35 (0.57) | CES2GPR35RXFP1NPSR1PRNP | |
| SCHEMBL4656286 | 0.86 | CES2 (0.61) | CES2RXFP1NPSR1PRNPTSHR | |
| SCHEMBL5453267 | 0.83 | RXFP1 (0.76) | RXFP1NPSR1PRNPTSHRMAPK1 | |
| SCHEMBL7400876 | 0.83 | MAPK1 (0.58) | CES2RXFP1NPSR1PRNPTSHR | |
| SCHEMBL15619574 | 0.81 | MCL1 (0.71) | CES2GPR35RXFP1NPSR1PRNP | |
| SCHEMBL4654240 | 0.81 | CES2 (0.56) | CES2RXFP1NPSR1PRNPTSHR | |
| SCHEMBL3493247 | 0.80 | L3MBTL1 (0.56) | CES2RXFP1NPSR1PRNPTSHR | |
| SCHEMBL5306006 | 0.79 | PRNP (0.51) | CES2RXFP1NPSR1PRNPTSHR | |
| SCHEMBL12153769 | 0.79 | MCL1 (0.71) | GPR35RXFP1NPSR1PRNPMAPK1 | |
| SCHEMBL2895162 | 0.79 | BCKDK (0.67) | CES2GPR35RXFP1NPSR1PRNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| EP-1740568-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORP (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1740568-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORP (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-1740568-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005077926-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| US-4551468-A | INDOLE, BENZOFURANS, BENZOTHIOPHENES | PFIZER INC. (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0050957-B1 | HETEROCYCLIC THROMBOXANE SYNTHETASE INHIBITORS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pfizer Limited (GB) | 1984-08-22 | — | — | EP | disclosed |
| US-4410539-A | Heterocyclic thromboxane synthetase inhibitors and pharmaceutical compositions containing them | PFIZER INC. (US) | 1983-10-18 | — | — | US | disclosed |
| EP-0050957-A1 | Heterocyclic thromboxane synthetase inhibitors, processes for their preparation, and pharmaceutical compositions containing them | Pfizer Limited (GB) | 1982-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | ABAT, BPTF, TNNT2 | CES2 484/4885GPR35 1720/4885RXFP1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.